(UroToday.com) Men with advanced hormone-sensitive prostate cancer (HSPC) starting long-term androgen deprivation therapy (ADT) follow a highly variable clinical course. Treatment intensification with docetaxel or androgen receptor-targeted therapies improves outcomes but there is a risk of overtreatment, especially in non-metastatic (M0) or metastatic (M1) low volume disease. As such, Dr. Emily Grist and colleagues established a framework for biomarker evaluation in the STAMPEDE trial, aiming to evaluate the feasibility and clinical utility of assessing the burden of copy number aberrations in newly diagnosed advanced HSPC. They hypothesized that an increased percentage of genome altered would associate with higher disease burden and worse prognosis. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Grist and colleagues presented the results of their study assessing copy number profiles of primary tumors for risk stratification of advanced prostate cancer in the STAMPEDE trial.